_1777294237270_124456903.png&w=48&q=75){kind=small}
Moderna stock doubles on skin cancer vaccine news
Merck and Moderna announced positive preliminary results from an advanced clinical trial of an experimental vaccine for melanoma skin cancer, based on mRNA technology. The vaccine, combined with the immune therapy drug Keytruda, achieved key endpoints in the Phase 3 trials involving over 1,100 patients, bringing closer the possibility of submitting a request for approval as a treatment for this type of cancer. The results of this study represent an important step toward developing an effective treatment for melanoma skin cancer, which accounts for a small percentage of skin cancers but is responsible for the majority of related deaths. Following the announcement, Moderna's shares nearly doubled, reflecting expectations that this vaccine could have broader therapeutic impacts in the future.
Notice: This Is an AI-Generated Summary
Comments (0)